Shares of Bioverativ Inc (NASDAQ:BIVV) have been given a consensus recommendation of “Hold” by the seventeen brokerages that are currently covering the firm, MarketBeat Ratings reports. Thirteen research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $61.88.
A number of analysts have recently weighed in on BIVV shares. William Blair reiterated a “hold” rating on shares of Bioverativ in a report on Thursday. Royal Bank of Canada increased their target price on shares of Bioverativ to $68.00 and gave the stock a “market perform” rating in a report on Thursday, January 18th. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $60.00 target price for the company in a report on Monday, January 1st. Jefferies Group increased their target price on shares of Bioverativ to $79.00 and gave the stock a “buy” rating in a report on Thursday, January 18th. Finally, Raymond James Financial lowered shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 23rd.
A number of institutional investors and hedge funds have recently modified their holdings of BIVV. Robeco Institutional Asset Management B.V. purchased a new stake in Bioverativ in the fourth quarter worth about $105,000. American Assets Investment Management LLC purchased a new stake in Bioverativ in the fourth quarter worth about $108,000. Advisors Asset Management Inc. purchased a new stake in Bioverativ in the third quarter worth about $137,000. Ladenburg Thalmann Financial Services Inc. purchased a new stake in Bioverativ in the third quarter worth about $190,000. Finally, Canada Pension Plan Investment Board purchased a new stake in Bioverativ in the third quarter worth about $194,000. Institutional investors and hedge funds own 97.18% of the company’s stock.
Shares of Bioverativ (BIVV) remained flat at $$104.98 during trading hours on Wednesday. Bioverativ has a 12-month low of $48.14 and a 12-month high of $105.01. The stock has a market cap of $11,360.00 and a PE ratio of 38.31.
Bioverativ (NASDAQ:BIVV) last announced its quarterly earnings data on Tuesday, February 13th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.01. Bioverativ had a return on equity of 40.99% and a net margin of 30.43%. The firm had revenue of $328.70 million for the quarter, compared to analysts’ expectations of $325.89 million. sell-side analysts anticipate that Bioverativ will post 3.82 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Bioverativ Inc (BIVV) Receives Consensus Rating of “Hold” from Brokerages” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/03/19/bioverativ-inc-bivv-receives-consensus-rating-of-hold-from-brokerages.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.